I'm confident that Agree Realty's monthly dividend can keep growing for many more years. The net lease REIT continues to have a massive sandbox to drive long-term AFFO per share growth. Agree Realty recently received an A- credit rating from Fitch, which further vindicates its disciplined and conservative approach to growth.

Agree Realty has underperformed Realty Income by about 11% in total returns over the past nine months. ADC's dividend yield spread over Treasuries has improved slightly but remains historically low, limiting its attractiveness compared to O. ADC's premium to NAV has narrowed, yet risks remain for a potential move to a deep discount, especially if NAV estimates fall.

Agree Realty (ADC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

While reaching retirement age can be both a blessing and a curse, relying on the U.S.

Dividend stocks are the cornerstone of a great investment portfolio. The right mix of dividend stocks can provide security for your funds as well as a growing passive income stream, which is why they are even more important for retirees.

Given heightened economic uncertainty, I am leaning more defensive and sticking with my dividend growth investing strategy, emphasizing diversification and income stability. The frozen housing market, soft labor conditions, and stagnating consumer spending signal potential economic weakness, despite optimism in select sectors like tech. My ETF portfolio review shows shifting leadership, with midstream energy outperforming previously, but preferreds and tech-focused ETFs now leading as trends evolve.

LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET. A webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

IO 2.0 + ADC 2.0 Strategy Builds a "Next-Generation" Platform with Global Competitive Edge Key Highlights: Final analysis of HARMONi-A Study: Ivonescimab met the overall survival (OS) endpoint, demonstrating a statistically significant and clinically meaningful OS benefit First international Phase III HARMONi study of Ivonescimab: High concordance between international and Chinese data Ivonescimab secures approval for first-line treatment of NSCLC (significant positive outcomes from HARMONi-2 compared to pembrolizumab) sNDA for ivonescimab in first-line treatment of sq-NSCLC (significant positive findings from HARMONi-6 compared to tislelizumab + chemotherapy) Global development of ivonescimab: 14 registrational/Phase III trials (8 for lung cancer + 5 for major tumors including cold tumors and IO-resistant indications) Cadonilimab approved for first-line treatment of cervical cancer (inclusive of all patient populations), addressing global gap in immunotherapy for PD-L1 negative patients First international registrational clinical trial for cadonilimab: second-line HCC Global development of cadonilimab: 11 registrational/Phase III trials (including major tumors in first-line and IO-resistant indications) Inclusion of ivonescimab and cadonilimab in National Reimbursement Drug List (NRDL) IO2.0 + ADC2.0 strategy rapidly advancing, with global clinical development of next-generation ADCs such as AK146D1 bispecific ADC Penpulimab receives U.S. FDA approval, validating Akeso's international development and registration capabilities Immunology and autoimmune breakthrough: ebdarokimab (IL-12/IL-23) received market approval, with successful Phase III trials for gumokimab (IL-17) and from manfidokimab (IL-4Rα) HONG KONG , Aug. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 interim results for the six month period ending June 30, 2025, highlighting record commercial sales in China and major global advances in its oncology and autoimmune pipelines. The company has strengthened its leadership in IO bispecific antibodies for first-line cancers, cold tumors, and IO-resistant indications, while rapidly progressing next-generation bispecific-ADC therapies.

Building resilient portfolios means pairing stocks with complementary strengths, like growth + income or stability + upside. I focus on combos that balance risk/reward, whether it's sector exposure, cash flow durability, or macroeconomic trends. In this article, I discuss two combos with a unique focus on consumer spending, housing, real estate, and energy.

Every month, we screen for higher-yielding dividend-paying stocks, but also those that have a trend of generally growing dividends. Those include dividend payers that screen well based on quant grades that suggest the dividends are relatively safe. We have two new names making the top of the list this month, which we haven't discussed before, but they unfortunately appear to have some real concerns.